...
首页> 外文期刊>World Journal of Gastroenterology >Drug-eluting fully covered self-expanding metal stent for dissolution of bile duct stones in vitro
【24h】

Drug-eluting fully covered self-expanding metal stent for dissolution of bile duct stones in vitro

机译:药物洗脱完全覆盖自膨胀金属支架,用于在体外溶解胆管石

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The treatment of difficult common bile duct stones (CBDS) remains a big challenge around the world. Biliary stenting is a widely accepted rescue method in patients with failed stone extraction under endoscopic retrograde cholangiopancreatography. Fully covered self-expanding metal stent (FCSEMS) has gained increasing attention in the management of difficult CBDS. To manufacture a drug-eluting FCSEMS, which can achieve controlled release of stone-dissolving agents and speed up the dissolution of CBDS. Customized covered nitinol stents were adopted. Sodium cholate (SC) and disodium ethylene diamine tetraacetic acid (EDTA disodium, EDTA for short) were used as stone-dissolving agents. Three different types of drug-eluting stents were manufactured by dip coating (Stent I), coaxial electrospinning (Stent II), and dip coating combined with electrospinning (Stent III), respectively. The drug-release behavior and stone-dissolving efficacy of these stents were evaluated in vitro to sort out the best manufacturing method. And the selected stone-dissolving stents were further put into porcine CBD to evaluate their biosecurity. Stent I and Stent II had obvious burst release of drugs in the first 5 d while Stent III presented controlled and sustainable drug release for 30 d. In still buffer, the final stone mass-loss rate of each group was 5.19% ± 0.69% for naked FCSEMS, 20.37% ± 2.13% for Stent I, 24.57% ± 1.45% for Stent II, and 33.72% ± 0.67% for Stent III. In flowing bile, the final stone mass-loss rate of each group was 5.87% ± 0.25% for naked FCSEMS, 6.36% ± 0.48% for Stent I, 6.38% ± 0.37% for Stent II, and 8.15% ± 0.27% for Stent III. Stent III caused the most stone mass-loss no matter in still buffer or in flowing bile, which was significantly higher than those of other groups (P 0.05). The novel SC and EDTA-eluting FCSEMS is efficient in diminishing CBDS in vitro. When conventional endoscopic techniques fail to remove difficult CBDS, SC and EDTA-eluting FCSEMS implantation may be considered a promising alternative.
机译:困难常见的胆管石(CBD)的治疗仍然是世界各地的一个大挑战。胆道支架是在内窥镜逆行胆管痴呆症下石萃取失效患者的广泛接受的救援方法。完全覆盖的自我膨胀金属支架(FCSEM)在难度CBD的管理中取得了越来越关注。制造一种药物洗脱的FCSEM,可以实现石溶剂的控制释放并加速CBD的溶解。采用定制覆盖的硝基醇支架。胆碱(SC)和二乙二胺四乙酸(EDTA二钠,短发)用作石材溶解剂。通过浸涂(支架I),同轴电刺刀(支架II)和与静电纺丝(支架III)联合的浸涂制造了三种不同类型的药物洗脱支架。在体外评估这些支架的药物释放行为和石材溶解的功效,以解决最佳制造方法。所选择的石材溶解的支架进一步进入猪CBD以评估它们的生物安全性。支架I和支架II在​​前5天中具有明显的药物爆发药物,而支架III呈现了30天的受控和可持续的药物释放。在静止的缓冲液中,裸FCSEM的每组最终的石头损失率为5.19%±0.69%,支架I的20.37%±2.13%,支架II的24.57%±1.45%,支架的33.72%±0.67% III。在流动胆汁中,裸FCSEM的每组最终的石头损失率为5.87%±0.25%,支架I的6.36%±0.48%,支架II的6.38%±0.37%,支架的8.15%±0.27% III。支架III在仍然缓冲或流动的胆汁中引起最多的石头损失,这显着高于其他群体(P 0.05)。新型SC和EDTA洗脱的FCSEM在体外减少CBD时是有效的。当常规内窥镜技术未能消除困难的CBD,SC和EDTA洗脱的FCSEMS植入可以被认为是有希望的替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号